Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

4427 - ICON8: A GCIG Phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment: Results of Primary Progression- Free Survival (PFS) analysis


08 Sep 2017


Gynaecological cancers


Cytotoxic Therapy;  Ovarian Cancer


Andrew Clamp


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


A.R. Clamp1, I. McNeish2, A. Dean3, D. Gallardo4, J. Weon- Kim5, D. O'Donnell6, J. Hook7, C. Coyle8, S.P. Blagden9, J. Brenton10, R. Naik11, T. Perren12, S. Sundar13, A. Cook8, E. James14, A.M. Swart15, S. Stenning8, R. Kaplan8, J. Ledermann16

Author affiliations

  • 1 Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, M20 4BX - Manchester/GB
  • 2 Institute Of Cancer Sciences, University of Glasgow, Glasgow/GB
  • 3 Oncology, St John of God Hospital, Subiaco/AU
  • 4 Clinical Oncology, Instituto Nacional de Cancerologia, Mexico/MX
  • 5 Obstetrics And Gynaecology, Seoul National University Hospital, 110-744 - Seoul/KR
  • 6 Department Of Medical Oncology, Cancer Trials Ireland, 8 - Dublin/IE
  • 7 Oncology, St. James's University Hospital Leeds, LS9 7TF - Leeds/GB
  • 8 Mrc Clinical Trials Unit, Institute of Clinical Trials and Methodology-UCL, WC2B6NH - London/GB
  • 9 Early Phase Clinical Trials Unit, Churchill Hospital University of Oxford, OX3 7LE - Oxford/GB
  • 10 Cruk-ci, Li Ka Shing Centre, Cancer Research UK, Cambridge Research Institute Addenbrooke's Hospital, CB2 0RE - Cambridge/GB
  • 11 Northern Gynaecology Oncology Centre, Queen Elizabeth Hospital, NE96SX - Gateshead/GB
  • 12 Leeds Institute Of Cancer And Pathology, St. James's University Hospital Leeds, LS9 7TF - Leeds/GB
  • 13 Pan- Birmingham Gynaecological Cancer Centre, University of Birmingham, B152SY - Birmingham/GB
  • 14 Statistics, Institute of Clinical Trials and Methodology-UCL, WC2B6NH - London/GB
  • 15 Norwich Clinical Trials Unit, University of East Anglia, Norwich/GB
  • 16 Cancer Research Uk & Ucl Cancer Trials Centre, UCL Cancer Institute, WC1 E 6BT - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4427


For several decades, standard first-line chemotherapy for EOC has been carboplatin (C) and paclitaxel (T), administered 3-weekly (q3w). The JGOG3016 trial reported clinically significant lengthening of PFS and overall survival in Japanese women using dose-dense weekly (q1w) T but with increased toxicity. ICON8 is a 3-arm trial, comparing standard q3w CT with dose-dense q1w regimens in a predominantly European patient group.


Eligible women with FIGO stage IcG3- IV EOC were randomised 1:1:1 to Arm 1 (standard) - q3w C AUC5/6 + q3w T 175mg/m2; Arm 2 - q3w C AUC5/6 + q1w T 80mg/m2; Arm 3 - q1w C AUC2 + q1w T 80 mg/m2. Patients entered ICON8 after immediate primary surgery (IPS), or received neo-adjuvant chemotherapy with planned delayed primary surgery (DPS). Primary intention to treat analysis compared arm 2v1 and arm 3v1 using methods for data with non-proportional hazards.


1566 women were randomised Jun 2011-Nov 2014. Median age- 62 years, 72% serous histology, 93% ECOG performance status 0/1. 48% had IPS, 50% planned DPS, 2% inoperable. 72%, 60%, 63% completed 6 cycles protocol-defined treatment in arms 1, 2, 3. Completion rate for 6 cycles platinum was 88% (90%; 89%; 85%). Paclitaxel dose-intensification was achieved (median total dose T (mg/m2)-1011; 1234; 1274). Grade (G) 3/4 toxicity (predominantly uncomplicated low neutrophils) was seen in 42%; 63%; 53% patients. Incidence of G3/4 febrile neutropenia (4%; 6%; 3%) and ≥G2 sensory neuropathy (28%; 25%; 23%) were similar across arms. At Feb 2017, 64% patients had experienced disease progression. No significant increase in PFS was observed with either weekly treatment (log-rank arm 2v1 p = 0.45; arm 3v1 p = 0.56, non-proportionality p = 0.02, restricted mean survival time=24.4; 24.9; 25.3 months in arms 1, 2, 3, median PFS- 17.9; 20.6; 21.1months, HR = 0.92 arm 2v1, HR = 0.94 arm 3v1).


Although weekly dose-dense chemotherapy can be delivered successfully as first-line EOC treatment without substantial toxicity increase, it does not significantly improve PFS compared to standard 3-weekly CT.

Clinical trial identification

ISRCTN: ISRCTN10356387 EUDRACT: 2010-022209-16 CTA: 2010-022209-16 ENGOT: OV-13 MREC: 11/LO/0043

Legal entity responsible for the study

Medical Research Council Clinical Trials Unit at University College London


Cancer Research UK; Medical Research Council


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.